首页> 外文期刊>Cancer and Metastasis Reviews >Fast neutron irradiation for prostate cancer.
【24h】

Fast neutron irradiation for prostate cancer.

机译:快速中子照射治疗前列腺癌。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to summarize the progress made using fast neutron irradiation in the treatment of prostate cancer at Wayne State University between 1991 and the year 2001. The results of three Phase II studies and one Phase III st udy involving nearly 700 patients is summarized in this paper. The Phase II studies weredose finding studies looking at doses of 15, 9, 10, and 11 nGy, respectively. The randomized protocol was a study of sequence looking at the results of treating patients with neutron first versus neutron radiation last. The results demonstrated that the best combination of tumor control probabilities and normal tissue complications was found in a mix of approximately 50% neutrons and 50% photons. Thus, the standard doses become 10 nGy and 40 Gy of photons. The randomized trial demonstrated that the sequence has significant importance and the disease-free survival was 93% for patients treated with neutrons first versus 73% for patients treated with neutrons last. There was no difference in the rate of acute or chronic complications. Finally, an analysis was performed demonstrating which patients may best benefit from the use of neutron irradiation. It was shown that patients with one, two, or three adverse risk factors had a significant improvement in disease-free survival when part of the treatment included neutron radiation versus standard photon radiation alone. Neutron radiation can be delivered safely with effort to see that it is superior to that which can be achieved by conformal photon irradiation by itself. Future work will be done to expand the role of neutron radiation in other clinical disease sites.
机译:这项研究的目的是总结1991年至2001年之间在韦恩州立大学使用快速中子辐照治疗前列腺癌所取得的进展。三项II期研究和一项涉及近700名患者的III期研究的结果是本文总结。 II期研究的剂量发现研究分别研究了15、9、10和11 nGy的剂量。随机方案是一项序列研究,旨在研究先中子后中子辐射治疗患者的结果。结果表明,在大约50%的中子和50%的光子的混合物中,发现了肿瘤控制概率和正常组织并发症的最佳组合。因此,标准剂量变为10 nGy和40 Gy光子。这项随机试验表明,该序列具有重要意义,首先接受中子治疗的患者的无病生存率为93%,而最后接受中子治疗的患者为73%。急性或慢性并发症的发生率没有差异。最后,进行了一项分析,表明哪些患者可能最受益于使用中子辐照。研究表明,当部分治疗包括中子辐射与仅标准光子辐射相比时,具有一,二或三个不利危险因素的患者的无病生存率显着提高。可以安全地传递中子辐射,以确保它优于自身通过共形光子辐照所能实现的辐射。未来的工作将扩大中子辐射在其他临床疾病部位的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号